君实生物-U
(688180)
| 流通市值：284.95亿 | | | 总市值：381.72亿 |
| 流通股本：7.66亿 | | | 总股本：10.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 500,591,459.94 | 1,948,317,315.72 | 1,271,200,009.95 | 786,056,275.43 |
| 营业收入 | 500,591,459.94 | 1,948,317,315.72 | 1,271,200,009.95 | 786,056,275.43 |
| 二、营业总成本 | 782,539,195.35 | 3,215,859,236.06 | 2,261,152,311.32 | 1,434,750,281.6 |
| 营业成本 | 93,900,960.88 | 410,682,338.47 | 325,339,075.87 | 210,419,748.58 |
| 税金及附加 | 5,961,832.38 | 22,293,299.83 | 17,132,866.24 | 11,611,663.96 |
| 销售费用 | 225,684,498.88 | 984,553,927.36 | 683,629,829.87 | 427,553,592.62 |
| 管理费用 | 97,024,040.85 | 523,203,972.13 | 353,242,444.41 | 239,719,730.6 |
| 研发费用 | 350,575,453.92 | 1,275,270,105.66 | 874,268,925.53 | 546,376,150.47 |
| 财务费用 | 9,392,408.44 | -144,407.39 | 7,539,169.4 | -930,604.63 |
| 其中:利息费用 | 16,807,655.37 | 43,941,768.23 | 32,912,225.93 | 20,686,103.23 |
| 其中:利息收入 | 7,407,783.93 | 43,630,497.26 | 32,647,344.93 | 24,453,746.85 |
| 加:公允价值变动收益 | -289,233.84 | -47,678,755.74 | -30,053,190.85 | -32,147,749.55 |
| 加:投资收益 | -10,369,937.82 | -23,553,900.59 | -17,147,524.18 | -27,835,848.07 |
| 资产处置收益 | 7,549,150.19 | 12,777,848.8 | 12,891,972.67 | 12,938,477.3 |
| 资产减值损失(新) | -5,810,755.08 | -88,178,776.72 | -3,641,769.04 | -381,606.68 |
| 信用减值损失(新) | 2,588,467.66 | 19,724,356.73 | 11,174,765.63 | 10,415,866.31 |
| 其他收益 | 6,564,179.02 | 55,626,310.84 | 47,607,041.87 | 10,019,476.8 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -281,715,865.28 | -1,338,824,837.02 | -969,121,005.27 | -675,685,390.06 |
| 加:营业外收入 | 6,866.57 | 2,251,713.09 | 877,766.7 | 818,405.29 |
| 减:营业外支出 | 5,128,115.8 | 20,984,057.46 | 16,400,811.52 | 9,290,891.21 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -286,837,114.51 | -1,357,557,181.39 | -984,644,050.09 | -684,157,875.98 |
| 减:所得税费用 | -27,250,675.73 | 22,551,676.87 | 4,081,640.85 | 3,551,165.51 |
| 六、净利润 | -259,586,438.78 | -1,380,108,858.26 | -988,725,690.94 | -687,709,041.49 |
| 持续经营净利润 | -259,586,438.78 | -1,380,108,858.26 | -988,725,690.94 | -687,709,041.49 |
| 归属于母公司股东的净利润 | -234,876,226.63 | -1,280,926,434.36 | -926,768,557.18 | -644,954,683.24 |
| 少数股东损益 | -24,710,212.15 | -99,182,423.9 | -61,957,133.76 | -42,754,358.25 |
| (一)基本每股收益 | -0.24 | -1.3 | -0.94 | -0.65 |
| (二)稀释每股收益 | -0.24 | -1.3 | -0.94 | -0.65 |
| 八、其他综合收益 | -10,204,644.58 | -17,870,045.74 | -47,944,698.9 | -24,342,498.84 |
| 归属于母公司股东的其他综合收益 | -10,204,644.58 | -17,870,045.74 | -47,944,698.9 | -24,342,498.84 |
| 九、综合收益总额 | -269,791,083.36 | -1,397,978,904 | -1,036,670,389.84 | -712,051,540.33 |
| 归属于母公司股东的综合收益总额 | -245,080,871.21 | -1,298,796,480.1 | -974,713,256.08 | -669,297,182.08 |
| 归属于少数股东的综合收益总额 | -24,710,212.15 | -99,182,423.9 | -61,957,133.76 | -42,754,358.25 |
| 公告日期 | 2025-04-26 | 2025-03-28 | 2024-10-30 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |